← Back to Search

Educational Messaging for COVID-19 Vaccine Uptake

N/A
Waitlist Available
Led By Sharon Johnston, MD
Research Sponsored by Hopital Montfort
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Non-vaccinated adults
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 months
Awards & highlights

Study Summary

This trial will help to identify the best ways to address vaccine hesitancy and improve uptake of the COVID-19 vaccine.

Who is the study for?
This trial is for non-vaccinated adults in Canada who are enrolled with a family physician participating in the CPIN network. It's not suitable for those who don't speak English or French.Check my eligibility
What is being tested?
The study tests whether tailored digital messages can reduce vaccine hesitancy and increase COVID-19 vaccination rates among patients of family physicians in Ontario, British Columbia, and New Brunswick.See study design
What are the potential side effects?
Since this trial involves communication strategies rather than medical treatments, there are no direct side effects related to drugs or medical interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have not received any vaccinations as an adult.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of hesitant individuals who received a COVID-19 vaccine
Secondary outcome measures
Individual willingness to receive a COVID-19 vaccine

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tailored COVID-19 vaccine messagingExperimental Treatment1 Intervention
Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.
Group II: Other health-related messagingActive Control1 Intervention
Patients assigned to the control group will receive health messages unrelated to COVID-19.

Find a Location

Who is running the clinical trial?

Public Health Agency of Canada (PHAC)OTHER_GOV
46 Previous Clinical Trials
94,933 Total Patients Enrolled
Hopital MontfortLead Sponsor
13 Previous Clinical Trials
4,975 Total Patients Enrolled
Eastern Ontario Health UnitUNKNOWN

Media Library

Tailored COVID-19 vaccine messages Clinical Trial Eligibility Overview. Trial Name: NCT04963790 — N/A
Coronavirus Research Study Groups: Tailored COVID-19 vaccine messaging, Other health-related messaging
Coronavirus Clinical Trial 2023: Tailored COVID-19 vaccine messages Highlights & Side Effects. Trial Name: NCT04963790 — N/A
Tailored COVID-19 vaccine messages 2023 Treatment Timeline for Medical Study. Trial Name: NCT04963790 — N/A
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top